Neuronetics Beats Q2 Revenue, Narrows Loss, and Lifts Margin Outlook

summarizeSummary

Neuronetics posted Q2 2026 revenue of $41.6M, up 9.1% and above estimates, with adjusted EBITDA turning positive. Full-year margin guidance was raised, though cash remains constrained and the going-concern risk lingers.

check_boxKey Events · Earnings and Guidance · STIM

• Q2 Revenue Beats, Up 9.1%

  Total revenue of $41.6M exceeded estimates, driven by 16.8% growth in Greenbrook clinic revenue to $26.9M. NeuroStar system revenue dipped 2.7% to $14.7M.

• Adjusted EBITDA Turns Positive

  Adjusted EBITDA reached $0.3M, a $5.9M improvement from a loss of $5.6M in Q2 2025, reflecting higher gross margin (51.1% vs. 46.6%) and lower operating expenses.

• FY 2026 Guidance Raised on Margins

  Full-year revenue guidance narrowed to $160M-$164M, gross margin raised to 48%-50%, and operating expenses (ex-SBC) lowered to $91M-$96M. Cash flow from operations and investing expected between -$10.5M and -$14.5M.

• Cash Position Remains Tight

  Cash and equivalents totaled $24.9M as of June 30, 2026, down from $34.1M at year-end 2025. Long-term debt stands at $61.5M. The going-concern warning from the Q1 10-Q remains a key risk.

auto_awesomeAnalysis · STIM · Industrial Applications And Services

A strong second quarter saw revenue climb 9.1% to $41.6M, topping estimates, while gross margin expanded to 51.1%. Adjusted EBITDA swung to a modest profit of $0.3M from a $5.6M loss a year ago, underscoring improving operational leverage. The company also raised its full-year gross margin guidance and trimmed its operating expense outlook. Still, cash remains tight at $24.9M against $61.5M in long-term debt, and the going-concern warning from the last 10-Q persists. Adding strategic pressure, an activist investor recently increased his stake and secured a board representation agreement. The results mark real progress toward profitability, but balance-sheet risk prevents a cleanly positive read.